What is recombinant activated factor VII?
Recombinant activated factor VII (rFVIIa; Novo Nordisk, Bagsvaerd, Denmark) is a hemostatic agent originally developed for the management of bleeding in haemophilia A and B patients with inhibitors to factor VIII or IX respectively.
What is recombinant factor VIIa used for?
In the United States, the FDA-approved indications for recombinant factor VIIa is for bypassing inhibitors to factors VIII and IX in patients with hemophilia A and B respectively and for treatment of congenital factor VII deficiency.
What is factor IX recombinant?
BeneFIX®, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adult and pediatric patients with hemophilia B (congenital factor IX deficiency or Christmas disease) for: control and prevention of bleeding episodes. peri-operative management.
What is NovoSeven for?
NovoSeven is a medicine used to treat and to prevent bleeding after surgical procedures.
What is factor 7 called?
Factor VII (EC 3.4. 21.21, formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme of the serine protease class.
Is Factor 7 a tissue factor?
Congenital Factor VII Deficiency. Factor VII is a vitamin K-dependent serine protease. The complex formed between activated factor VII (VIIa) and an integral membrane protein tissue factor, exposed on the vascular lumen upon injury, is considered to be the main trigger of blood clotting.
How do you administer a factor of 7?
First, invert the NovoSeven® RT vial and slowly draw the solution into the syringe. Next, detach the syringe from the vial adapter by turning the syringe counterclockwise. Attach the syringe to the luer end of an infusion needle set. Then, inject the reconstituted NovoSeven® RT intravenously slowly over 2 to 5 minutes.
Is NovoSeven activated?
Activation. NovoSeven® RT binds directly to activated platelets, activating FX to produce FXa. FXa complexes with other factors to convert prothrombin to thrombin.
What is factor 7 deficiency called?
Factor VII deficiency was first described in the medical literature by Dr. Alexander, et al. in 1951 and was referred to as prothrombin conversion accelerator deficiency. The disorder has also been known as Alexander’s disease.
What is the treatment of factor 7 deficiency?
Specific treatment options for acute bleeds in individuals with factor VII deficiency include recombinant factor VII, prothrombin complex concentrates, and fresh frozen plasma. Antifibrinolytics such as aminocaproic acid can help alleviate the bleeding symptoms.